Clinical trial
SB-743921 In Patients With Solid Tumors
NCT00136513 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00136513 |
|---|---|
| Title | SB-743921 In Patients With Solid Tumors |
| Official title | A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Administration of SB743921 on a Once Every 3 Week Schedule in Patients With Solid Tumors |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumor Cancer |
| Intervention type | Drug |
| Interventions | SB-743921 |
| Enrollment | 30 |
| Start date | Apr 1, 2004 |
| First posted | Aug 29, 2005 |
| Last update posted | Oct 16, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: